Literature DB >> 21180623

Menstrual migraine: therapeutic approaches.

E Anne Macgregor1.   

Abstract

The development of diagnostic criteria has enabled greater recognition of menstrual migraine as a highly prevalent and disabling condition meriting specific treatment. Although few therapeutic trials have yet been undertaken in accordance with the criteria, the results of those published to date confirm the efficacy of acute migraine drugs for symptomatic treatment. If this approach is insufficient, the predictability of attacks provides the opportunity for perimenstrual prophylaxis. Continuous contraceptive strategies provide an additional option for management, although clinical trial data are limited. Future approaches to treatment could explore the genomic and nongenomic actions of sex steroids.

Entities:  

Keywords:  menstrual migraine; perimenstrual prophylaxis; therapy

Year:  2009        PMID: 21180623      PMCID: PMC3002599          DOI: 10.1177/1756285609335537

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  54 in total

1.  Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration.

Authors:  B W Somerville
Journal:  Neurology       Date:  1975-03       Impact factor: 9.910

2.  Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.

Authors:  G Allais; G Acuto; X Cabarrocas; R Esbri; C Benedetto; G Bussone
Journal:  Neurol Sci       Date:  2006-05       Impact factor: 3.307

3.  Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study.

Authors:  E A MacGregor; A Frith; J Ellis; L Aspinall; A Hackshaw
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

4.  Prospective analysis of factors related to migraine attacks: the PAMINA study.

Authors:  C Wöber; W Brannath; K Schmidt; M Kapitan; E Rudel; P Wessely; C Wöber-Bingöl
Journal:  Cephalalgia       Date:  2007-04       Impact factor: 6.292

5.  Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine.

Authors:  Robert Nett; Steve Landy; Steve Shackelford; Mary S Richardson; Michael Ames; Michelle Lener
Journal:  Obstet Gynecol       Date:  2003-10       Impact factor: 7.661

6.  Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.

Authors:  Michael M Tuchman; Angela Hee; Ugochi Emeribe; Stephen Silberstein
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.

Authors:  Stephen D Silberstein; Arthur H Elkind; Curtis Schreiber; Charlotte Keywood
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

Review 8.  Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials.

Authors:  A Edelman; M F Gallo; M D Nichols; J T Jensen; K F Schulz; D A Grimes
Journal:  Hum Reprod       Date:  2006-03       Impact factor: 6.918

9.  Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women.

Authors:  F Granella; G Sances; C Zanferrari; A Costa; E Martignoni; G C Manzoni
Journal:  Headache       Date:  1993 Jul-Aug       Impact factor: 5.887

10.  Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache.

Authors:  Vincent Martin; Suzanne Wernke; Karen Mandell; Willie Zoma; Judy Bean; Susan Pinney; James Liu; Nabih Ramadan; Robert Rebar
Journal:  Headache       Date:  2003-04       Impact factor: 5.887

View more
  4 in total

Review 1.  Women and Migraine: the Role of Hormones.

Authors:  Candice Todd; Ana Marissa Lagman-Bartolome; Christine Lay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-31       Impact factor: 5.081

2.  Menstrual migraine: treatment options.

Authors:  L C Newman; M S Yugrakh
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

3.  A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine.

Authors:  Jemima S A Dzator; Peter R C Howe; Kirsten G Coupland; Rachel H X Wong
Journal:  Nutrients       Date:  2022-04-22       Impact factor: 6.706

4.  Burden of migraine related to menses: results from the AMPP study.

Authors:  Jelena M Pavlović; Walter F Stewart; Christa A Bruce; Jennifer A Gorman; Haiyan Sun; Dawn C Buse; Richard B Lipton
Journal:  J Headache Pain       Date:  2015-03-18       Impact factor: 7.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.